Mark DeLong - Jul 15, 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Senior Vice President
Signature
/s/ David Watson, attorney-in-fact for Mark Delong
Stock symbol
APLS
Transactions as of
Jul 15, 2021
Transactions value $
-$46,780
Form type
4
Date filed
7/16/2021, 06:40 PM
Previous filing
Jun 16, 2021
Next filing
Jul 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $15.5K +1K +10.54% $15.52 10.5K Jul 15, 2021 Direct F1
transaction APLS Common Stock Sale -$62.3K -1K -9.53% $62.30 9.49K Jul 15, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -1K -2.27% $0.00 43K Jul 15, 2021 Common Stock 1K $15.52 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise from an established 10B5-1 trading plan.
F2 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.